Abstract
Introduction The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China, in December 2019, and has since spread worldwide.[1] This study attempts to summarize current evidence regarding major inflammatory markers, severity predictors and its impact on outcome, which provide current clinical experience and treatment guidance for this novel coronavirus.
Methods This is a retrospective observational study done at an urban teaching covid-19 designated hospital. Hospital data were analysed with aim of studying inflammatory markers, predictors and outcome. Patients were classified in Mild, Moderate, Severe & Critical categories of COVID cases. Their clinical parameters, laboratory investigations, radiological findings & Outcome measures were studied. Strength of association & correlation of those parameters with severity and in-hospital mortality were studied.
Results A total 204 (N) patients were clinically classified into different severity groups, as per MOHFW and qCSI(quick Covid Severity Index) guidelines, as Mild (34), Moderate (56), Severe (39) and Critical (75). The mean(SD) age of the cohort was 55.1+13.2 years; 74.02% were male. Severe COVID-19 illness is seen more in patients more than 50 years of age. COVID-19 patients having IHD develop worse disease with excess early in-hospital mortality. Respiratory rate & Heart Rate on admission are correlated with severe and stormy disease. Among Inflammatory markers, on admission LDH, D-Dimer and CRP are related with severity and excess in-hospital death rate.
Conclusion Advanced age, male gender, IHD, Respiratory Rate & Heart Rate on admission were associated with severe covid-19 illness. S. Lactate Dehydrogenase & D-dimer was associated with severe covid-19 illness and early in-hospital death.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No Funds Received for the purpose of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NHL Institutional Review Board (Name of IRB/IEC) approved the Protocol for the study in full review meeting conducted on 09.09.2020. ETHICS STATEMENT: This study was conducted independently without any external source of funding. Highest code of conduct was followed with utmost credibility ensured. The study was conducted after approval from Institutional Review Board (NHL Institutional review Board). Patient data were anonymized to maintain confidentiality of patient privacy.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding source: No FUNDING RECEIVED
Any Presentation Previously Done?: None
Registration number: Not Applicable
Conflict of Interest: None to Disclose from Any Author
M. 9898286644
Email: drnehalshah1929{at}gmail.com
M. 9825447813
Email: drjanak.research{at}gmail.com
M. 6354929539
Email:tiwarihemant1{at}rediffmail.com
M- 9825493960
Email : blackbuck3{at}gmail.com
M- 8511773245
Email : vishal.r.beriwala{at}gmail.com
Data Availability
Data is available with hospital and statistical datasheet is available for sharing in case needed after approval from Institutional Review Board.